<DOC>
	<DOCNO>NCT02121197</DOCNO>
	<brief_summary>To review safety efficacy injection Ozurdex ( 700 μg dexamethasone ) clinical practice management patient DME .</brief_summary>
	<brief_title>Retrospective Trial Efficacy Safety Intravitreal Ozurdex Patients With Diabetic Macular Edema .</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Adults ( ≥18 year ) diabetes DME study eye ( eyes DME eye include analysis ) BCVA minimum 20/200 ( 35 letter ) Central Macular Thickness ( CMT ) ≥300 µm Patients DME treat Ozurdex least twice ( baseline first Ozurdex injection ) . Follow least 6 month last Ozurdex injection give Complete record include BCVA ( OCT Fluorescein Angiography ( FA ) available ) throughout follow Patients ME secondary Diabetes Mellitus ( DM ) . Presence retinopathy ( AMD , RVO ) visually significant ocular morbidity ( e.g . advanced glaucoma , corneal opacity ) Previous ocular trauma surgery cataract extraction Intravitreal triamcinolone ≤6 month baseline Intravitreal bevacizumab , ranibizumab , pegaptanib &lt; 1 month baseline Marked intraocular pressure ( IOP ) elevation response previous steroid treatment Ocular Hypertension ( OHT ) study eye ( ) IOP &gt; 23 mm Hg without antiglaucoma medication IOP &gt; 21 mm Hg one antiglaucoma medication Use 2 antiglaucoma medication Glaucoma Visual Fields ( VF ) defect &gt; 4 dB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Macular Diabetic Edema</keyword>
	<keyword>Ozurdex</keyword>
	<keyword>Retrospective</keyword>
	<keyword>European</keyword>
	<keyword>Intra-vitreal injection</keyword>
</DOC>